Fort Point Capital Partners LLC purchased a new stake in Eli Lilly and Co (NYSE:LLY) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,947 shares of the company’s stock, valued at approximately $333,000.
Other institutional investors have also bought and sold shares of the company. Avestar Capital LLC purchased a new stake in shares of Eli Lilly and in the fourth quarter valued at approximately $100,000. Gradient Investments LLC purchased a new stake in Eli Lilly and during the fourth quarter worth $103,000. MPS Loria Financial Planners LLC purchased a new stake in Eli Lilly and during the second quarter worth $128,000. San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and during the second quarter worth $129,000. Finally, Front Row Advisors LLC purchased a new stake in Eli Lilly and during the fourth quarter worth $137,000. Hedge funds and other institutional investors own 77.62% of the company’s stock.
LLY has been the topic of a number of research analyst reports. Morgan Stanley boosted their target price on Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 21st. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, December 5th. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and boosted their target price for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Goldman Sachs downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $86.98 to $95.00 in a research report on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. Eli Lilly and has a consensus rating of “Hold” and a consensus target price of $93.47.
In related news, insider Donald A. Zakrowski sold 860 shares of the company’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $76.50, for a total value of $65,790.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the transaction, the insider now owns 4,130 shares of the company’s stock, valued at $334,901.70. The disclosure for this sale can be found here. Insiders sold 12,261 shares of company stock worth $987,485 over the last 90 days. Company insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and stock opened at $80.49 on Monday. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01. Eli Lilly and Co has a 12-month low of $73.69 and a 12-month high of $89.09. The stock has a market capitalization of $88,184.67, a price-to-earnings ratio of -402.43, a PEG ratio of 1.50 and a beta of 0.28.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The business had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. During the same period in the prior year, the business earned $0.95 earnings per share. The business’s revenue was up 7.0% on a year-over-year basis. sell-side analysts anticipate that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/19/fort-point-capital-partners-llc-invests-333000-in-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.